TAUBERIAN THEOREMS FOR THE WEIGHTED MEAN METHOD OF SUMMABILITY OF INTEGRALS

Let $q$ be a positive weight function on $\mathbf{R}_{+}:=[0, \infty)$ which is integrable in Lebesgue's sense over every finite interval $(0,x)$ for $00$, $Q(0)=0$ and $Q(x) \rightarrow \infty$ as $x \to \infty$.Given a real or complex-valued function $f \in L^{1}_{loc} (\mathbf{R}_{+})$, we define $s(x):=\int_{0}^{x}f(t)dt$ and$$\tau^{(0)}_q(x):=s(x), \tau^{(m)}_q(x):=\frac{1}{Q(x)}\int_0^x \tau^{(m-1)}_q(t) q(t)dt\,\,\, (x>0, m=1,2,...),$$provided that $Q(x)>0$. We say that $\int_{0}^{\infty}f(x)dx$ is summable to $L$ by the $m$-th iteration of weighted mean method determined by the function $q(x)$, or for short, $(\overline{N},q,m)$ integrable to a finite number $L$ if$$\lim_{x\to \infty}\tau^{(m)}_q(x)=L.$$In this case, we write $s(x)\rightarrow L(\overline{N},q,m)$. It is known thatif the limit $\lim _{x \to \infty} s(x)=L$ exists, then $\lim _{x \to \infty} \tau^{(m)}_q(x)=L$ also exists. However, the converse of this implicationis not always true. Some suitable conditions together with the existence of the limit $\lim _{x \to \infty} \tau^{(m)}_q(x)$, which is so called Tauberian conditions, may imply convergence of $\lim _{x \to \infty} s(x)$. In this paper, one- and two-sided Tauberian conditions in terms of the generating function and its generalizations for $(\overline{N},q,m)$ summable integrals of real- or complex-valued functions have been obtained. Some classical type Tauberian theorems given for Ces\`{a}ro summability $(C,1)$ and weighted mean method of summability $(\overline{N},q)$ have been extended and generalized. 

Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry

Patients at high risk for sudden cardiac death (SCD) may benefit from wearable cardioverter defibrillators (WCD) by avoiding immediate implantable cardioverter defibrillator (ICD) implantation. Different factors play an important role including patient selection, compliance and optimal drug treatment. We aimed to present real world data from 4 centers from Germany and Switzerland. Between 04/2012 and 03/2019, 708 patients were included in this registry. Patients were followed up over a mean time of 28 ± 35.5 months. Outcome data including gender differences and different etiologies of cardiomyopathy were analyzed. Out of 708 patients (81.8% males, mean age 61.0 ± 14.6), 44.6% of patients had non-ischemic cardiomyopathy, 39.8% ischemic cardiomyopathy, 7.9% myocarditis, 5.4% prior need for ICD explantation and 2.1% channelopathy. The mean wear time of WCD was 21.2 ± 4.3 h per day. In 46% of patients, left ventricular ejection fraction (LVEF) was > 35% during follow-up. The younger the patient was, the higher the LVEF and the lower the wear hours per day were. The total shock rate during follow-up was 2.7%. Whereas an appropriate WCD shock was documented in 16 patients (2.2%), 3 patients received an inappropriate ICD shock (0.5%). During follow-up, implantation of a cardiac implantable electronic device was carried out in 34.5% of patients. When comparing German patients (n = 516) to Swiss patients (n = 192), Swiss patients presented with longer wear days (70.72 ± 49.47 days versus 58.06 ± 40.45 days; p = 0.001) and a higher ICD implantation rate compared to German patients (48.4% versus 29.3%; p = 0.001), although LVEF at follow-up was similar between both groups. Young age is a negative independent predictor for the compliance in this large registry. The most common indication for WCD was non-ischemic cardiomyopathy followed by ischemic cardiomyopathy. The compliance rate was generally high with a decrease of wear hours per day at younger age. Slight differences were found between Swiss and German patients, which might be related to differences in mentality for ICD implantation

Proširenost virusa virusnog proljeva u tkivima spolnog sustava goveda.

In this study, the cellular localisation and distribution of BVD viral antigens in genital system tissues were investigated in 65 non-pregnant dairy cows and in 65 bulls. For this study genital system tissue samples, taken from slaughtered bulls with no pathological lesions and from females having reproductive problems, were marked using the immunoperoxidase method on their paraffin sections. BVD viral antigens were determined in 15 of the 65 non-pregnant dairy cows (consistent with cell culture results) using the indirect immunoperoxidase method. BVD viral antigens were present in macrophage-like cells in the stroma of the ovaries and uterus. No BVD viral antigens were observed in the samples of testicles, epididymis, vesicula seminalis, or prostate in the male animals. In all animals, including BVDV-positive ones, no pathologic lesions were observed, except periodically non-specific subepithelial or stromal mononuclear cell infiltrations. Most of these cells were seen to be formed by lymphocytes and macrophages.Istražena je lokalizacija i proširenost antigena virusa virusnog proljeva goveda u tkivima spolnog sustava 65 negravidnih mliječnih krava i 65 bikova. U tu svrhu rabljen je imunoperoksidazni test na histološkim rezovima tkiva. Tom metodom pretraženi su uzorci tkiva spolnih organa uzeti od zdravih zaklanih bikova te krava s reprodukcijskim poremećajima. Virusni antigeni dokazani su u 15 od 65 krava (sukladno s uzgojem virusa na staničnoj kulturi). Antigeni su bili prisutni u makrofagima sličnim stanicama unutar strome jajnika i maternice. Virusni antigeni nisu dokazani u uzorcima tkiva testisa, epididimisa, sjemene vrećice i prostate bikova. U pretraženih životinja, uključujući i one pozitivne na virus, nisu zabilježene patološke promjene, osim povremenih nespecifičnih subepitelijalnih ili stromalnih mononuklearnih infiltracija limfocitima i makrofagima

Ectopic adrenal tissues at orchidopexy in children: A case series

Ectopic adrenal tissue is rare in children. Although its excision is recommendedwhen found incidentally during inguinal surgical procedures, routine explorationis not indicated for the detection of its presence. Here, we present eight cases ofectopic adrenal tissue in pediatric patients who underwent orchidopexy

C-REACTIVE PROTEIN LEVELS IN OBSTRUCTIVE SLEEP APNEA PATIENTS

Amaç: Obstrüktif Uyku Apne Sendromu (OUAS)'u olan hastalarda C-Reaktif Protein (CRP)'in erken ateroskleozun saptanmasında kullanılması. Yöntemler: Çalışmaya Dokuz Eylül Üniversitesi Tıp Fakültesi uyku bozukluğu polikliniğine başvuran, yaşları 20-66 arasında olan toplam 45 obez hasta alındı. Hastaların cinsiyet, yaş, boy, kilo değerleri saptandı. Vücut kitle indeksleri, bel / kalça oranları hesaplandı. Polisomnografi tetkiki yapıldı. OUAS'u olan hasta grubu ve OUAS'u olmayan kontrol grubu olarak iki gruba ayrıldı. Her iki grup hastadan açlık venöz kan örneği alınarak yüksek duyarlılıklı CRP düzeyleri ve lipid profilleri çalışıldı. B-mode dopler ultrasonografiyle karotis intima madia kalınlıkları ölçüldü. Bulgular: Kontrol grubunda yd-CRP düzeyleri 0,22 (0,01-0,57) mg/dl, OUAS'lı hasta grubundaysa 0,30 (0,05-1,52) mg/dl olarak bulundu, iki grup arasında istatiksel olarak anlamlı fark saptanmadı (p=0,300). Karotis İntima Media Kalınlığı (KİMK) ölçümleri değerlendirildiğinde her iki grup arasında istatistiksel olarak anlamlı fark saptandı (p=0,01). Bel / kalça oranları belirlenip, abdominal obezite açısından değerlendirildiğinde iki grup arasında istatistiksel olarak anlamlı fark gözlendi (p<0,01). AKŞ, TK ve LDL-K düzeylerinde de anlamlı fark saptandı (p=0,049, p=0,01 ve p=0,03). Sonuç: OUAS'lı hastalarda abdominal obezite, AKŞ, TK ve LDL-K düzeylerinde istatistiksel olarak anlamlı fark saptanması OUAS metabolik sendrom ilişkisi için varolan kanıtları doğruladı. Bununla birlikte, ölçülen CRP düzeylerinin OUAS'u hastalarında erken aterosklerozun gösterilmesinde iyi bir gösterge olmayabileceği belirlendi. Objective: To determine whether CRP can detect subclinic atherosclerosis in obstructive sleep apnea patients. Methods: Ages between 20-66, 45 obese patient who was have application to D.E.Ü. Medical Faculty sleep laboratory recruited to study. We determine sex, age, height and weight for all patients and calculate body mass index, waist / hip raito. Polisomnographia was done. Patient's divided in to two group's, whose PSG detected OSA constitute patients group and whose PSG not detected OSA constitude control group. We obtained fasting venous blood sample and measure HSCRP and lipid profiles. Carotis intima media thickness measured with B-mode doppler ultrasonography. Results: HSCRP found 0,22 (0,01-0,57) mg/dl in control group and 0,30 (0,05-1,52) mg/dl in OSA patients group, we didn't detect statistical significancy (p=0,300). When Carotid İntima Media Thickness (CIMT) measurements evaluated for each group, statistical significancy find (p=0,01). WHR determined and evaluated for abdominal obesity, statistical significancy found between two group (p<0,01). Also significant differece detected for FBG, TK and LDL-K (p=0,049, p=0,01 and p=0,03). Conclusion: Detected significant difference for abdominal obesity, FBG, TK and LDL-K levels in OSA patients confirmed existing evidence of relation eith sleep apnea and metabolic syndrome. Although we determined, measured HSCRP levels may not be a good marker for presenting subclinic atherosclerosis in OSA patients

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed